Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
Matthew S. Davids(Dana-Farber Cancer Institute), Ulrich Jäger(Comprehensive Cancer Center Vienna), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Julio Delgado(Departament de Salut), Stephan Stilgenbauer(Universität Ulm), Constantine S. Tam(The Alfred Hospital), Marco Montillo(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), James Essell(Oncology Hematology Care), Bryone J. Kuss(Flinders Medical Centre), Carol Moreno(Hospital de Sant Pau), Hagop Youssoufian(Verastem (United States)), David T. Weaver(University of North Carolina Health Care), Paolo Ghia(Vita-Salute San Raffaele University), Zsolt Nagy(Semmelweis University), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Stephanie Lustgarten(Ariadne Diagnostics (United States))
Cited by 43
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k